Bristol-Myers Squibb CompanyBMYNYSE
Loading
Cash Flow PerformanceStrong
Percentile Rank79
3Y CAGR+2.4%
5Y CAGR-0.7%
Year-over-Year Change
Operating cash flow minus capital expenditures
3Y CAGR
+2.4%/yr
vs +18.2%/yr prior
5Y CAGR
-0.7%/yr
Recent acceleration
Acceleration
-15.8pp
Decelerating
Percentile
P79
Within normal range
vs 5Y Ago
1x
Modest growth
Streak
1 yr
Consecutive declineStrong
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $12.85B | -7.9% |
| 2024 | $13.94B | +10.2% |
| 2023 | $12.65B | +5.9% |
| 2022 | $11.95B | -21.6% |
| 2021 | $15.23B | +14.5% |
| 2020 | $13.30B | +80.3% |
| 2019 | $7.37B | +20.6% |
| 2018 | $6.12B | +44.9% |
| 2017 | $4.22B | +129.0% |
| 2016 | $1.84B | - |